Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
NCT05141721
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
- NCT05141721 ↗
- Active, not recruiting
- Seattle Project Corporation
- Focused
We haven't built an HCP commentary report on NCT05141721 (GRT-C901, GRT-R902 and 4 more in Colorectal Neoplasms) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05141721 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
- Phase
- Phase 2/Phase 3
- Status
- Active, not recruiting
- Conditions
- Colorectal Neoplasms
- Interventions
- GRT-C901; GRT-R902; Atezolizumab; Ipilimumab; Fluoropyrimidine plus leucovorin; Bevacizumab
- Arms
- Vaccine Arm · Experimental
- Control Arm · Active comparator
- Enrollment
- 700 (estimated)
- Primary outcomes
- Phase 2: Molecular response defined as ≥ 30% decrease from baseline in circulating tumor DNA (ctDNA)
- Phase 3: Progression-free survival per Immune-based Response Evaluation Criteria in Solid Tumors (iRECIST) as assessed by blinded independent review committee (IRC)
- Sponsor
- Seattle Project Corporation
- Start
- Feb 12, 2022
- Primary completion
- Mar 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05141721 · updated May 16, 2025